Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Leukemia, Promyelocytic, Acute 1Leukemia, Prolymphocytic, T-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

ruxolitinib 3venetoclax 2fludarabine phosphate 2duvelisib 2thymoglobulin 1romidepsin 1itacitinib 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Lisaftoclax 1Depsipeptides 1Cyclosporins 1Cyclosporine 1Cladribine 1Busulfan 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, T-Cell × Lisaftoclax × 1 year × Clear all
NCT04496349 2025-11-04

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Ascentage Pharma Group Inc.

Phase 2 Recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡